Teva reacts to third-quarter results, delays laquinimod
Following mixed third-quarter results, Teva Pharmaceutical has reduced its full-year forecast and has announced it will delay seeking US approval for multiple sclerosis medication laquinimod.
Following mixed third-quarter results, Teva Pharmaceutical has reduced its full-year forecast and has announced it will delay seeking US approval for multiple sclerosis medication laquinimod.
Although group sales rose 2.2% to $4.34bn, Teva suffered from tumbling turnover in the US, falling 48% to $845m owing to emerging generic competition.
Teva has now adjusted its 2011 sales forecast to between $18.3bn and $18.6bn, down from the $18.5bn-$19bn it originally predicted.
Teva chief executive Shlomo Yanai also revealed that laquinimod will be held back, adding that the company would continue to work with the US Food and Drug Administration in order to determine the best design for an additional trial.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Pharmaceutical Technology Excellence Awards - The Benefits of Entering
Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!
Excellence in Action NorthWest EHealth has won three 2025 Pharmaceutical Technology Excellence Awards for Innovation, Safety and Diversity. Explore how its ConneXon platformis transforming SAE reporting and real-time safety oversight, while FARSITE delivers socio-economically inclusive recruitment to boost trial efficiency, data integrity and regulatory-grade representativeness.
